Treating stress response with chemokine receptor CCR5 modulators

Details for Australian Patent Application No. 2003207646 (hide)

International Classifications

Event Publications

17 July 2003 Complete Application Filed

Priority application(s): 60/365,097 18.03.02 US; 60/350,868 22.01.02 US

18 September 2003 Application Open to Public Inspection

Published as AU-B-2003207646

25 January 2007 Application Accepted

Published as AU-B-2003207646

24 May 2007 Standard Patent Sealed

17 April 2008 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 13 Mar 2008. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

18 September 2008 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 13 Mar 2008

12 March 2009 Assignment Registered

Merck & Co., Inc.; Vanderbilt University The patent has been assigned to Vanderbilt University

19 August 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.